Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (<sup>111</sup>In)/Yttrium 90 (<sup>90</sup>Y) Ibritumomab Tiuxetan (Zevalin<sup>®</sup>) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels

Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (<sup>111</sup>In)/Yttrium 90 (<sup>90</sup>Y) Ibritumomab Tiuxetan (Zevalin<sup>®</sup>) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels

Purpose: We prospectively evaluated the feasibility of SPECT-CT/planar organ dosimetry-based radiation dose escalation radioimmunotherapy in patients with recurrent non-Hodgkin’s lymphoma using the theranostic pair of <sup>111</sup>In and <sup>90</sup>Y anti-CD20 ibritumomab...

Full description

Bibliographic Details
Main Authors: Richard L. Wahl, Eric C. Frey, Heather A. Jacene, Brad S. Kahl, Steven Piantadosi, Jesus A. Bianco, Richard J. Hammes, Miah Jung, Wayne Kasecamp, Bin He, George Sgouros, Ian W. Flinn, Lode J. Swinnen
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
radioimmunotherapy
dosimetry
quantitative SPECT imaging
anti CD20
lymphoma
theranostics
Online Access:https://www.mdpi.com/2072-6694/13/11/2828

Similar Items

Similar Items